MX2020000293A - Microrna-455-3p como un marcador bioperiferico para la enfermedad de alzheimer. - Google Patents

Microrna-455-3p como un marcador bioperiferico para la enfermedad de alzheimer.

Info

Publication number
MX2020000293A
MX2020000293A MX2020000293A MX2020000293A MX2020000293A MX 2020000293 A MX2020000293 A MX 2020000293A MX 2020000293 A MX2020000293 A MX 2020000293A MX 2020000293 A MX2020000293 A MX 2020000293A MX 2020000293 A MX2020000293 A MX 2020000293A
Authority
MX
Mexico
Prior art keywords
patient
alzheimer
disease
dataset
microrna
Prior art date
Application number
MX2020000293A
Other languages
English (en)
Inventor
Reddy P Hemachandra
Subodh Kumar
Original Assignee
Univ Texas Tech System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas Tech System filed Critical Univ Texas Tech System
Publication of MX2020000293A publication Critical patent/MX2020000293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención incluye un método para identificar un paciente de la enfermedad de Alzheimer (AD) antes de alcanzar la clasificación de enfermedad clínica, que comprende: obtener un conjunto de datos asociados con una muestra de sangre, suero, o plasma del paciente, en donde el conjunto de datos comprende datos que representan el nivel de uno o más biomarcadores microARN en la muestra de sangre, suero, o plasma; evaluar el conjunto de datos para detectar una presencia o un aumento en una cantidad de miRNA-445-3p; determinar la probabilidad de que el paciente desarrollará AD antes de alcanzar la clasificación de enfermedad clínica al detectar la presencia o el aumento en miRNA-445-3p para producir una puntuación que sea indicativa de una probabilidad de desarrollar AD, en donde una puntuación más alta con relación a un control sano indica que es probable que el paciente tenga la prognosis para hacer transición a la AD clasificada, en donde el control sano se deriva de un paciente que no tiene AD sin evidencia clínica de AD.
MX2020000293A 2017-07-12 2018-07-12 Microrna-455-3p como un marcador bioperiferico para la enfermedad de alzheimer. MX2020000293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531760P 2017-07-12 2017-07-12
PCT/US2018/041840 WO2019014457A1 (en) 2017-07-12 2018-07-12 MICROARN-455-3P AS A PERIPHERAL BIOMARKER OF ALZHEIMER'S DISEASE

Publications (1)

Publication Number Publication Date
MX2020000293A true MX2020000293A (es) 2020-07-22

Family

ID=65002342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000293A MX2020000293A (es) 2017-07-12 2018-07-12 Microrna-455-3p como un marcador bioperiferico para la enfermedad de alzheimer.

Country Status (6)

Country Link
US (2) US11492669B2 (es)
EP (1) EP3652340A4 (es)
AU (1) AU2018300159A1 (es)
CA (1) CA3069445A1 (es)
MX (1) MX2020000293A (es)
WO (1) WO2019014457A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3178889A1 (en) 2020-03-31 2021-10-07 Toray Industries, Inc. Kit or device and method for detecting hippocampal atrophy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100960256B1 (ko) 2001-02-27 2010-06-01 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 유사분열 촉진인자-활성화 단백질 키나제 인산화에 근거한 알쯔하이머병 진단
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
WO2009009457A1 (en) * 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Alzheimer's disease-specific micro-rna microarray and related methods
US8420800B2 (en) * 2009-04-16 2013-04-16 Keio University Head-and-neck tumor proliferation inhibitor
EP2699666B1 (en) * 2011-04-18 2016-10-05 DiamiR, LLC miRNA-BASED UNIVERSAL SCREENING TEST (UST)
RU2639509C2 (ru) 2011-06-27 2017-12-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. МикроРНК - БИОМАРКЕРЫ, УКАЗЫВАЮЩИЕ НА БОЛЕЗНЬ АЛЬЦГЕЙМЕРА
EP2742155B1 (en) * 2011-08-08 2018-01-24 Advanced Genomic Technology LLC Biomarker for alzheimer's disease and/or mild cognitively impairment
WO2013036936A1 (en) 2011-09-09 2013-03-14 Van Andel Research Institute Microrna biomarkers for diagnosing parkinson's disease
US20140303025A1 (en) * 2013-03-15 2014-10-09 The Translational Genomics Research Institute Methods for the diagnosis and prognosis of neurodegenerative diseases
WO2015179909A1 (en) * 2014-05-26 2015-12-03 The University Of Melbourne Mirna biomarkers of alzheimer's disease
CN104774929B (zh) * 2015-03-18 2017-06-30 中山大学肿瘤防治中心 miR‑455‑3p在食管鳞状细胞癌中的诊断、治疗和预后的应用
KR101998457B1 (ko) * 2016-05-10 2019-07-10 조선대학교산학협력단 알츠하이머 질병의 진단을 위한 바이오마커
ES2965473T3 (es) * 2017-06-19 2024-04-15 St Johns Univ Biomarcadores de microARN en suero circulante y métodos para el diagnóstico de la enfermedad de Alzheimer

Also Published As

Publication number Publication date
US20200354790A1 (en) 2020-11-12
US11492669B2 (en) 2022-11-08
EP3652340A1 (en) 2020-05-20
AU2018300159A1 (en) 2020-02-06
US20200255899A1 (en) 2020-08-13
WO2019014457A1 (en) 2019-01-17
CA3069445A1 (en) 2019-01-17
WO2019014457A8 (en) 2019-02-28
EP3652340A4 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
Nagasawa et al. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
EA201370063A1 (ru) Фосфолипидом рака
AR088827A1 (es) Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
Li et al. MiR-664a-3p expression in patients with obstructive sleep apnea: a potential marker of atherosclerosis
MY182773A (en) Method for indicating a presence or non-presence of aggressive prostate cancer
NZ608384A (en) Biomarkers of renal injury
Tokumitsu et al. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy
MY179845A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
WO2013036754A3 (en) Methods and compositions for diagnosis of ovarian cancer
WO2018097614A3 (ko) 유방암 환자의 화학치료 유용성 예측 방법
He et al. High expression of S100A6 predicts unfavorable prognosis of lung squamous cell cancer
Tang et al. Investigation of LINC00342 as a poor prognostic biomarker for human patients with non–small cell lung cancer
Nie et al. Long non‑coding RNA BACE1‑AS is an independent unfavorable prognostic factor in liver cancer
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
MX2020000293A (es) Microrna-455-3p como un marcador bioperiferico para la enfermedad de alzheimer.
WO2014177867A3 (en) Differentially expressed biomarkers for alzheimer's disease
MX2017010516A (es) Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea.
Marques et al. Genome-scale RNA interference profiling of Trypanosoma brucei cell cycle progression defects
Zhu et al. A Prediction Rule for Overall Survival in Non‐Small‐Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm